A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants

Description

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of VX-973 in healthy participants.

Conditions

Pain

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of VX-973 in healthy participants.

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of VX-973 in Healthy Adults

A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants

Condition
Pain
Intervention / Treatment

-

Contacts and Locations

Salt Lake City

ICON Salt Lake City, Salt Lake City, Utah, United States, 84124

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
  • * A total body weight of more than (\>) 50 kg
  • * Participants of non-childbearing potential
  • * Nonsmoker or ex-smoker for at least 3 months before screening
  • * History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
  • * Any condition possibly affecting drug absorption, distribution, metabolism, or excretion

Ages Eligible for Study

18 Years to 55 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Vertex Pharmaceuticals Incorporated,

Study Record Dates

2025-10